Nexentis Technologies Inc. (NXTS) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Nexentis Technologies Inc. (formerly N2OFF, Inc.) operates primarily through two segments: Biotechnology (via wholly-owned subsidiary MitoCareX, acquired in October 2025) and Renewable Energy (via NITO Renewable Energy and joint ventures). The company recently completed a strategic shift by selling its former Save Foods Ltd. subsidiary to Voice Assist, Inc. in March 2026, classifying Save Foods as discontinued operations. The company is a smaller reporting company and an emerging growth company listed on the Nasdaq Capital Market.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue (Continuing Ops) | $0 | $0 |
| Net Loss (Total) | $(6,589,000) | $(1,257,000) |
| Net Loss (Continuing Ops) | $(7,424,000) | $(1,116,000) |
| Net Gain (Discontinued Ops) | $835,000 | $(141,000) |
| Cash and Cash Equivalents | $4,299,000 | $2,724,000 |
| Working Capital | $6,483,000 | $3,359,000 |
| Total Debt (Short-term + Credit Facility) | $467,000 | $977,000 |
| Goodwill Impairment | $(6,291,000) | $0 |
Material Changes vs. Prior Period
- Goodwill Impairment: A non-cash impairment loss of $6.3 million was recorded for the MitoCareX reporting unit due to a decline in the company's stock price and market capitalization, as well as geopolitical risks in the Middle East.
- Discontinued Operations: The company recognized a $835,000 gain from the deconsolidation and sale of Save Foods Ltd. to Voice Assist, Inc., compared to a loss in the prior year. This transaction resulted in the company receiving a 19.99% equity stake in Voice Assist.
- Operating Expenses: General and administrative expenses increased by 278% to $1.9 million, driven primarily by share-based compensation ($1.15 million) and professional services. R&D expenses were $275,000, reflecting the integration of MitoCareX.
- Stock Structure: A 1-for-7 reverse stock split was effected on April 8, 2026, to regain Nasdaq compliance. All historical share data in the filing has been retroactively adjusted.
Guidance, Outlook, and Risks
- Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern. While current cash is projected to fund operations through Q1 2027, the company relies on future equity financing or strategic partnerships to sustain operations.
- Geopolitical Risk: Operations are heavily concentrated in Israel (MitoCareX). Escalating conflicts involving Iran and Hezbollah pose significant risks to R&D timelines, personnel safety, and asset valuation.
- Capital Needs: The company intends to raise additional capital through its Standby Equity Purchase Agreement (SEPA) or other equity/debt instruments. Failure to secure funding could force a reduction in development scope or cessation of operations.
- Outlook: The company is focused on advancing MitoCareX's oncology therapeutics (targeting SLC25A proteins) and developing solar projects in Europe (Italy, Poland, Germany) via Solterra partnerships.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $4.3 million cash balance against the projected burn rate for MitoCareX R&D and solar project development.
- Financing Capacity: Confirm the remaining availability under the SEPA with YA II PN, Ltd. and the terms of the Pure Capital credit facility.
- Geopolitical Exposure: Assess the specific impact of the Israel-Iran conflict on MitoCareX's clinical trial timelines and supply chain.
- Contingent Consideration: Review the remaining liability for MitoCareX acquisition milestones ($929,000 recorded) and the potential for future dilution or cash outflows.
- Reverse Split Impact: Monitor post-split trading volume and compliance with Nasdaq minimum bid price requirements.